www.ijarp.com ISSN 2456-9992 Page: 01-21

International Journal Advanced Research Publications

Review Article

Volume: 02

Issue: 06

ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL FORMULATION AND AI-DRIVEN ADVANCED DRUG DELIVERY SYSTEMS: CURRENT ADVANCES, CLINICAL APPLICATIONS, AND FUTURE PERSPECTIVES

Amar M. Raval[1]*, Kajal M. Doshi[2]

[1]Associate Professor, Department of Pharmaceutics

Sharda School of Pharmacy, Pethapur, Gandhinagar-382610, Gujarat, India.

[2]Assistant Professor, Department of Pharmaceutics,

Shri B. M. Shah College of Pharmaceutical Education and Research, Modasa-383315, Gujarat, India.

Article Received: 28 April 2026, Article Revised: 18 May 2026, Published on: 08 June 2026

***Corresponding Author: Amar M. Raval**

Associate Professor, Department of Pharmaceutics Sharda School of Pharmacy, Pethapur, Gandhinagar-382610, Gujarat, India.

DOI: https://doi-doi.org/101555/ijarp.3165

ABSTRACT

Artificial Intelligence (AI) has emerged as a transformative technological force across pharmaceutical sciences, significantly reshaping traditional formulation development and advanced drug delivery system design. Conventional pharmaceutical formulation has historically relied on empirical experimentation and repeated trial-and-error approaches, which are often time-consuming, expensive, and associated with high development failure rates. The integration of Artificial Intelligence-including Machine Learning (ML), Deep Learning (DL), Artificial Neural Networks (ANN), and predictive analytics-has introduced data-driven and computationally intelligent strategies that improve formulation design, optimize process parameters, and accelerate decision-making throughout the pharmaceutical development lifecycle.

AI-based pharmaceutical formulation enables prediction of physicochemical compatibility between active pharmaceutical ingredients and excipients, estimation of solubility and dissolution behavior, optimization of particle engineering, and improvement of dosage form stability. In advanced drug delivery systems, AI has demonstrated significant utility in designing nanoparticles, liposomes, polymeric carriers, microneedles, transdermal patches, and controlled-release systems by improving precision, targeting capability, and release kinetics. Furthermore, AI-supported predictive modeling has strengthened Quality by Design (QbD), real-time monitoring, digital manufacturing, and regulatory compliance within pharmaceutical industries.

Clinical applications of AI-driven drug delivery include oncology, diabetes management, vaccine delivery, biologics, personalized therapeutics, and chronic disease treatment, where computational models enhance therapeutic precision while improving patient adherence and minimizing adverse effects. Emerging technologies such as digital twins, wearable delivery platforms, and AI-assisted personalized medicine are expected to further expand pharmaceutical innovation.

This review critically discusses the principles of Artificial Intelligence in pharmaceutical formulation, highlights recent advances in AI-assisted drug delivery technologies, explores current clinical applications, and evaluates future opportunities and limitations in integrating intelligent systems into pharmaceutical care and drug development.

KEYWORDS: Artificial Intelligence, pharmaceutical formulation, machine learning, advanced drug delivery systems, nanoparticles, personalized medicine, predictive analytics

1. INTRODUCTION

The pharmaceutical industry has undergone significant transformation over the past two decades due to increasing therapeutic complexity, rising development costs, and the growing demand for personalized and precision-based medicine. Traditional formulation development relies heavily on experimental screening and sequential optimization, which require substantial labor, time, and financial investment. Although this approach has supported successful drug development for decades, increasing molecular complexity and strict regulatory expectations have highlighted limitations in conventional formulation methods.

Modern drug discovery pipelines frequently produce highly lipophilic molecules, biologics, peptides, and targeted therapeutics with complex physicochemical properties. These molecules present challenges including poor aqueous solubility, low permeability, chemical instability, dose variability, and formulation incompatibility. At the same time, patients increasingly demand safer therapies, improved convenience, and personalized dosing.

Artificial Intelligence has emerged as an advanced computational approach capable of transforming pharmaceutical sciences by converting experimental datasets into predictive knowledge. AI systems use algorithms capable of learning patterns from existing pharmaceutical data and generating predictions regarding formulation behavior, process performance, and therapeutic outcomes.

In pharmaceutical formulation, AI supports:

- excipient selection
- compatibility prediction
- dosage optimization
- stability forecasting
- dissolution modeling
- manufacturing parameter control

In drug delivery systems, AI improves:

- nanoparticle design
- controlled release
- targeted delivery
- transdermal penetration
- individualized therapy

As pharmaceutical sciences transition toward digitalization and precision medicine, Artificial Intelligence is becoming central to next-generation formulation research.

2. Fundamentals of Artificial Intelligence in Pharmaceutical Sciences

Artificial Intelligence refers to computer systems capable of performing tasks requiring human-like learning, prediction, reasoning, and data interpretation.

Major AI approaches used in pharmaceutical sciences include:

2.1 Machine Learning

Machine learning identifies patterns from pharmaceutical datasets and predicts outcomes.

Common methods:

- Random Forest
- Support Vector Machine
- Decision Trees
- Gradient Boosting

Applications:

- dissolution prediction

- formulation optimization
- quality control

2.2 Deep Learning

Deep learning uses multi-layer neural networks.

Useful for:

- complex image analysis
- manufacturing pattern recognition
- molecular property prediction

2.3 Artificial Neural Networks

ANN mimics biological neural processing.

Applications:

- release kinetics
- tablet hardness
- excipient compatibility
- process optimization

2.4 Predictive Analytics

Supports:

- stability forecasting
- failure prediction
- shelf-life estimation

Table 1. AI technologies used in pharmaceutical formulation.

AI approach	Pharmaceutical use	Benefit
Machine learning	dissolution prediction	faster optimization
Deep learning	molecular analysis	improved precision
ANN	release modeling	better dosage control
Predictive analytics	stability forecasting	reduced failure
Digital twins	process simulation	real-time optimization

3. Artificial Intelligence in Pharmaceutical Formulation Development

AI is increasingly used in formulation development because it reduces reliance on repetitive experimentation.

3.1 Excipient compatibility prediction

AI predicts:

- API-polymer miscibility
- degradation interaction
- moisture sensitivity

Benefits:

- rapid screening
- improved stability
- reduced formulation failure

3.2 Solubility and dissolution prediction

AI predicts:

- aqueous solubility
- supersaturation
- dissolution kinetics

Useful in:

- solid dispersions
- nanosuspensions
- amorphous systems

3.3 Process optimization

AI assists with:

- blending time
- granulation variables
- compression force
- drying conditions

Improves:

- reproducibility
- efficiency
- scale-up

3.4 Quality by Design

AI supports QbD through:

- critical parameter analysis
- risk assessment

- predictive control

4. AI-Driven Advanced Drug Delivery Systems

AI is highly valuable in advanced delivery technologies.

4.1 Nanoparticles

AI predicts:

- particle size
- surface charge
- encapsulation efficiency

Applications:

- oncology
- targeted delivery

4.2 Liposomes

AI improves:

- lipid ratio
- vesicle stability
- release behavior

4.3 Microneedles

AI models:

- insertion force
- geometry
- drug permeation

4.4 Controlled-release systems

AI predicts:

- release profile
- polymer degradation
- therapeutic window

4.5 Smart wearable delivery

AI supports:

- glucose-responsive systems
- real-time dosing

- personalized monitoring

Table 2. AI-driven advanced drug delivery systems.

Delivery system	AI application	Clinical benefit
Nanoparticles	size optimization	targeted therapy
Liposomes	stability prediction	longer circulation
Microneedles	geometry modeling	painless delivery
Implants	release prediction	sustained therapy
Wearables	adaptive dosing	personalized care

5. Clinical Applications of AI-Driven Pharmaceutical Formulation and Drug Delivery Systems

Artificial Intelligence has significantly expanded beyond research laboratories and has begun influencing clinical pharmaceutical practice through advanced formulation design, patient-specific therapy optimization, and intelligent drug delivery systems. The integration of predictive computational tools into clinical therapeutics has improved precision in medicine, reduced adverse effects, accelerated treatment response, and supported individualized care.

AI-assisted pharmaceutical delivery is particularly beneficial in disease conditions requiring narrow therapeutic control, long-term drug administration, variable dose adjustment, and targeted site-specific delivery. In such cases, conventional fixed-dose therapy often fails to provide optimal therapeutic outcomes because patient physiology, disease progression, and metabolic response differ considerably.

AI-driven systems analyze extensive clinical datasets, pharmacokinetic patterns, disease biomarkers, and therapeutic response trends. These analyses help formulate delivery systems capable of adapting to patient-specific requirements and improving clinical performance.

Major therapeutic areas showing substantial advancement include oncology, diabetes, vaccine development, biologics, neurological disorders, cardiovascular medicine, antimicrobial therapy, and personalized medicine.

5.1 Oncology and Targeted Anticancer Drug Delivery

Cancer therapy requires highly precise drug delivery because conventional chemotherapy often produces severe systemic toxicity and damages healthy tissues. Therapeutic effectiveness depends on maintaining drug concentration at tumor tissue while minimizing exposure to normal cells.

Artificial Intelligence has become highly valuable in anticancer formulation because it enables prediction of tumor targeting, optimization of nanoparticle behavior, and personalization of therapy according to tumor biology.

AI models evaluate:

- Tumor receptor expression
- Permeability characteristics
- Intracellular uptake
- Nanoparticle surface behavior
- Release kinetics
- Expected toxicity

These models improve formulation of:

- Liposomes
- Polymeric Nanoparticles
- Ligand-targeted carriers
- Antibody-drug conjugates
- Implantable depot systems

Clinical benefits include:

- Higher tumor-specific accumulation
- Reduced systemic toxicity
- Optimized dose selection
- Prolonged therapeutic action
- Improved patient survival outcomes

AI also helps predict drug resistance and supports adaptive treatment modification.

5.2 Diabetes and Smart Insulin Delivery

Diabetes mellitus requires continuous therapeutic control and regular dose adjustment. Traditional insulin therapy often causes variability due to inconsistent absorption and delayed dose modifications.

AI-driven pharmaceutical systems have transformed diabetes management by integrating formulation science with continuous monitoring.

These systems include:

- smart insulin pumps
- glucose-responsive transdermal patches
- microneedle insulin delivery
- wearable biosensor-guided drug release

AI continuously analyzes:

- blood glucose trends
- insulin sensitivity
- meal timing
- activity level
- previous therapeutic response

This allows automated optimization of insulin delivery.

Clinical advantages:

- tighter glycemic control
- fewer hypoglycemic episodes
- better patient adherence
- reduced dosing errors
- improved long-term disease management

Microneedle insulin patches are particularly promising because they provide painless administration and can be programmed for controlled release.

5.3 Vaccine Delivery and Immunization Technologies

AI has contributed significantly to vaccine formulation and delivery.

Traditional vaccine development often requires extensive formulation screening and repeated stability testing. AI accelerates this process by predicting formulation compatibility and delivery performance.

Applications include:

- lipid nanoparticle vaccine systems
- mRNA stabilization
- antigen delivery optimization
- microneedle vaccination patches
- thermostability prediction

AI predicts:

- antigen degradation

- immune response
- carrier compatibility
- dose distribution
- shelf-life stability

Clinical benefits include:

- faster vaccine development
- improved vaccine stability
- enhanced immune response
- simplified administration
- broader population coverage

Microneedle vaccine patches may further improve immunization by enabling painless self-administration and reducing cold-chain dependency.

5.4 Biologics and Peptide Delivery

Biologics and peptide therapeutics are among the most challenging pharmaceutical products because they are highly sensitive to temperature, pH, enzymatic degradation, and formulation stress.

AI assists formulation scientists in:

- protein stability prediction
- peptide degradation modeling
- carrier compatibility analysis
- aggregation prediction
- release optimization

Delivery systems include:

- injectable depots
- polymeric nanoparticles
- transdermal microneedles
- implantable sustained-release systems

Clinical benefits:

- reduced degradation
- prolonged therapeutic action
- improved bioavailability
- enhanced patient compliance

Important therapeutic examples:

- insulin analogs
- monoclonal antibodies
- GLP-1 receptor agonists
- growth hormones

5.5 Neurological and CNS Drug Delivery

The central nervous system remains difficult to target because of the blood-brain barrier.

AI helps predict:

- molecular permeability
- carrier transport
- receptor targeting
- CNS pharmacokinetics

AI-guided systems include:

- nanocarriers
- intranasal delivery systems
- controlled release implants

Clinical applications:

- Parkinson's disease
- epilepsy
- Alzheimer's disease
- brain tumors

Benefits:

- better CNS penetration
- reduced systemic toxicity
- sustained brain exposure

Table 3. Major clinical applications of AI-driven drug delivery systems.

Therapeutic area	AI-supported delivery system	Major benefit	Clinical outcome
Oncology	nanoparticles, liposomes	tumor targeting	reduced toxicity
Diabetes	insulin pumps, microneedles	automated dosing	glycemic control
Vaccines	lipid nanoparticles	stability	improved immunization
Biologics	depot systems	sustained release	higher adherence
Neurology	CNS nanocarriers	BBB penetration	targeted therapy
Cardiovascular	controlled release implants	dose precision	long-term control
Infectious disease	targeted antimicrobials	optimized exposure	resistance reduction

6. Benefits of Artificial Intelligence in Pharmaceutical Development

Artificial Intelligence offers broad scientific and industrial advantages.

6.1 Faster development

AI rapidly analyzes data and predicts formulation outcomes.

Benefits:

- Reduced experimental cycles
- Shorter development timelines
- Faster commercialization

6.2 Cost reduction

Predictive modeling reduces:

- Failed trials
- Material waste
- Repeated experimentation

6.3 Improved precision

AI identifies optimal:

- Excipient ratios
- Particle size
- Release profile

6.4 Better quality control

AI improves:

- Process monitoring
- Batch consistency
- Predictive maintenance

6.5 Personalized medicine

AI enables patient-specific dose and delivery customization.

Table 4. Benefits of AI in pharmaceutical sciences.

Benefit	Impact on formulation	Industrial value
Faster prediction	quicker screening	shorter launch timeline
Cost reduction	fewer failed batches	lower development cost
Accuracy	optimized formulation	better reproducibility
Real-time monitoring	quality assurance	regulatory compliance
Personalization	patient-specific therapy	improved outcomes

7. CHALLENGES AND LIMITATIONS

Despite major progress, several challenges remain.

Data limitations

AI depends on large, reliable datasets.

Regulatory uncertainty

Validation standards are evolving.

Infrastructure cost

Implementation may be expensive.

Model bias

Poor datasets reduce accuracy.

Cybersecurity

Digital systems require protection.

Human expertise

AI supports-but does not replace-scientific judgment.

Table 5. Challenges and practical limitations.

Challenge	Description	Impact
Limited datasets	insufficient data	poor prediction
Regulation	unclear AI guidelines	approval delay
Cost	software + hardware	limited adoption
Bias	inaccurate learning	formulation error
Security	data exposure	compliance concern
Validation	reproducibility	regulatory difficulty

8. Future Perspectives

The future of pharmaceutical sciences will increasingly depend on intelligent and connected systems.

Expected advances:

- autonomous formulation laboratories
- AI-driven robotic experimentation
- digital twins of manufacturing
- wearable smart drug delivery
- precision medicine platforms
- predictive pharmacovigilance
- AI-assisted regulatory review

Integration of AI with:

- nanotechnology
- biotechnology
- 3D printing
- wearable biosensors

will likely transform pharmaceutical care.

Table 6. Future trends in AI-driven pharmaceutical sciences.

Emerging technology	Application	Expected impact
Digital twins	virtual process simulation	faster optimization
Smart wearables	responsive delivery	personalized therapy
AI robotics	formulation automation	reduced labor
Predictive pharmacovigilance	adverse event monitoring	improved safety
3D printing	personalized dosage	dose flexibility
Precision therapeutics	individualized treatment	better clinical outcomes

Table 7. Summary of Major Applications of Artificial Intelligence in Pharmaceutical Formulation and Drug Delivery Systems.

Sr. No.	Application area	AI tools commonly used	Key pharmaceutical application	Major benefit	Clinical/industrial significance
1	Drug–excipient compatibility prediction	Machine Learning (ML), Artificial Neural Networks (ANN)	Predicting API–excipient interactions, miscibility, degradation risk	Faster formulation screening and improved stability	Reduces formulation failure and improves shelf life
2	Solubility and dissolution prediction	ML, Deep Learning (DL)	Predicting aqueous solubility and dissolution behavior of APIs	Better bioavailability optimization	Supports development of poorly soluble drugs
3	Solid dispersion optimization	ANN, predictive analytics	Polymer selection and amorphous stability prediction	Improved dissolution and reduced recrystallization	Useful in oral solid dosage formulation
4	Nanoparticle formulation design	ML, DL	Predicting particle size, zeta potential, and encapsulation efficiency	Enhanced targeting and improved carrier stability	Widely used in oncology and targeted delivery

5	Liposome and vesicular system development	ANN, ML	Optimization of lipid ratio and drug release behavior	Better entrapment and controlled release	Useful for biologics and anticancer formulations
6	Microneedle-based transdermal delivery	Predictive modeling, ML	Needle geometry, insertion force, and skin permeation analysis	Painless and efficient transdermal drug delivery	Applied in insulin, vaccines, and biologics
7	Controlled-release dosage systems	ANN, ML	Predicting release kinetics and polymer degradation	Sustained therapeutic action and dose control	Improves patient compliance
8	Manufacturing process optimization	ML, predictive analytics	Granulation, blending, compression, and drying control	Reduced process variability and improved efficiency	Supports industrial scale-up
9	Quality by Design (QbD) and process analytical technology	AI-driven modeling	Real-time monitoring and process parameter control	Better quality consistency	Important for regulatory compliance
10	Personalized medicine and precision dosing	ML, wearable AI systems	Patient-specific dose adjustment and formulation design	Improved therapeutic response	Major future direction in healthcare
11	Vaccine formulation and delivery	DL, ML	Antigen stability and lipid nanoparticle optimization	Faster vaccine development and improved immunogenicity	Important in mRNA and advanced vaccines
12	Regulatory decision support and formulation analytics	Predictive analytics, AI platforms	Data analysis and formulation documentation	Faster review and improved decision-making	Supports pharmaceutical regulatory processes

Artificial Intelligence has become an important tool throughout pharmaceutical formulation and advanced drug delivery development. It supports accurate prediction, reduces development time, improves manufacturing efficiency, enhances product quality, and enables personalized treatment approaches, making it highly valuable in both pharmaceutical research and clinical practice.

9. CONCLUSION

Artificial Intelligence has emerged as one of the most influential technologies in modern pharmaceutical formulation and advanced drug delivery system development.

Its ability to analyze complex pharmaceutical data, predict formulation behavior, optimize process variables, and personalize therapy has substantially improved both pharmaceutical manufacturing and clinical therapeutic outcomes.

AI-driven technologies have shown remarkable value in oncology, diabetes, vaccine delivery, biologics, and neurological therapeutics. Their integration with advanced delivery platforms such as nanoparticles, microneedles, implantable depots, and wearable devices continues to expand possibilities for targeted and patient-centered treatment.

Although limitations related to data quality, infrastructure, and regulatory validation remain, future pharmaceutical innovation is expected to increasingly rely on AI-assisted systems.

The integration of pharmaceutical sciences with Artificial Intelligence represents a major transition toward faster development, safer medicines, improved patient adherence, and truly personalized healthcare delivery.

REFERENCES

1. Rathi S, Shah S, Raval AM, Patel D, Goswami A. Physicochemical characterization and in-vitro dissolution enhancement of ranolazine using solid dispersion method. JETIR. 2019;6(3):866-878.
2. Prajapati A, Yadav P, Raval AM, Patel J. Review on solid dispersion-based fast dissolving tablets formulation approaches. World J Pharm Med Res. 2025;11(11):109-112
3. Abdalla Y, Nandiraju LP, Yue H, De Monsales CB, Yeung C, Basit AW. Artificial intelligence-enabled personalisation of oral drug delivery: from data-driven design to on-demand manufacturing. Adv Drug Deliv Rev. 2026 Jun;233:115855. doi:10.1016/j.addr.2026.115855. PMID: 41833742.
4. Suksaeree J, et al. AI-enabled, QbD-aligned predictive and sustainable pharmaceutical formulation development using natural polymer-based drug delivery systems: current progress and future perspectives. Int J Biol Macromol. 2026;281:141008. doi:10.1016/j.ijbiomac.2026.141008.
5. Jiang J, et al. Applications of AI and machine learning in accelerating the development of pharmaceutical formulations and advanced therapeutic systems. Drug Discov Today. 2026;31(4):104322. doi:10.1016/j.drudis.2026.104322.

6. Winkler DA, et al. Synergies between data science methods and innovative pharmaceutical drug delivery technologies: opportunities and emerging trends. Adv Drug Deliv Rev. 2026;230:115741. doi:10.1016/j.addr.2026.115741.
7. Ogundemuren DA, et al. Artificial intelligence and machine learning in smart vaginal drug delivery systems: formulation strategies and future therapeutic perspectives. Eur J Pharm Biopharm. 2026;205:114380. doi:10.1016/j.ejpb.2026.114380. PMID: 42055249.
8. Singh CK, et al. Recent trends in the development and clinical translation of polymeric nanoparticles for targeted drug delivery. Int J Pharm. 2026;657:124982. doi:10.1016/j.ijpharm.2026.124982.
9. Kumar S, et al. Artificial intelligence and machine learning driven nanorobotics for targeted brain delivery: redefining blood-brain barrier navigation. J Control Release. 2026;353:456-472. doi:10.1016/j.jconrel.2026.02.011.
10. Esmaeilpour D, et al. Artificial intelligence-driven protein design and sustainable nanocarrier engineering for next-generation pharmaceutical delivery systems. Acta Pharm Sin B. 2026;16(5):2218-2236. doi:10.1016/j.apsb.2026.01.014.
11. Biomarker-guided drug delivery systems and oral therapeutics: integrating artificial intelligence, machine learning, and nanotechnology in precision medicine. Drug Deliv Transl Res. 2026;16(3):811-828. doi:10.1007/s13346-026-01562-1.
12. Ros H, et al. Artificial intelligence and machine learning guided design and optimisation of advanced drug delivery systems: a translational perspective. J Control Release. 2026;351:998-1017. doi:10.1016/j.jconrel.2026.01.028
13. Allen LV. Pharmaceutical dosage forms and drug delivery systems. Philadelphia: Lippincott Williams & Wilkins; 2020.
14. Aulton ME. Pharmaceutics: the design and manufacture of medicines. London: Churchill Livingstone; 2018.
15. Zankhwala FM, Raval AM, Kushkiwala AM, Sarvaiya SP, Raval KK, Thakar NJ, et al. Formulation and evaluation of optimized polymer blends for diclofenac diethylamine transdermal system. Rev Diabet Stud. 2025;21(S9):701-708.
16. Kushkiwala AM, Zankhwala FM, Patel MD, Raval AM. Flurbiprofen loaded ethosomal gel: design, optimization and anti-inflammatory activity. Int J Res Anal Rev. 2024;11(4):709-720.
17. Falwariya R, Jethva T, Raval AM, Lokhande D. Comprehensive review: microneedle patches - a painless revolution in transdermal drug delivery. World J Pharm Med Res. 2026;12(1):199-207.

18. Bhatt R, Raval AM, Patel J, Patel D. Oral thin film drug delivery systems for thrombosis therapy. Int J Pharm Sci. 2026;4(1):3563-3576.
19. Mevada J, Patel K, Raval AM. Materiovigilance: the growing importance of materiovigilance systems. Int J Pharm Sci. 2026;4(1):962-974.
20. Patel N, Raval AM. Gastroretentive drug delivery system: a review. Int J Pharm Sci. 2026;4(1):734-742.
21. Raval AM, Bhavsar PR, Pandya FU, Patel DK. Co-processed excipients in pharmaceutical formulation: advances and applications. Asian J Pharm Res Dev. 2026;14(1):105-113.
22. Jain NK. Controlled and novel drug delivery systems. New Delhi: CBS Publishers; 2019.
23. Thakor AD, Dharajiya RM, Shaikh MZ, Raval AM. A review on neuropharmacology: mechanisms, drug classes and clinical applications. Asian J Pharm Res Dev. 2026;14(1):114-121.
24. Raval AM, Suthar AM, Durani B, Thakar NJ, Zankhwala FM, Kushkiwala AM, et al. Smart co-processed excipient platforms for multifunctional optimization of ibuprofen tablet formulations. J Appl Bioanal. 2025;11(S15):103-128.
25. Sinko PJ. Martin's Physical Pharmacy and Pharmaceutical Sciences. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2011.
26. Remington JP. Remington: The Science and Practice of Pharmacy. 22nd ed. London: Pharmaceutical Press; 2013.
27. Florence AT, Attwood D. Physicochemical Principles of Pharmacy. 6th ed. London: Pharmaceutical Press; 2016.
28. Mevada J, Patel K, Raval AM. Materiovigilance: From device failure to safety reform, the growing importance of materiovigilance systems. Int J Pharm Sci. 2026;4(1):962-74.
29. Falwariya, R., Jethva, T., Raval, A.M. and Lokhande, D., 2026. Comprehensive review: Microneedle patches-A painless revolution in transdermal drug delivery. World J Pharm Med Res, 12(1), pp.199-207.
30. Mevada J, Patel K, Raval AM. Role of pharmacovigilance in drug safety monitoring. World J Pharm Med Res. 2025;11(11):235-40.
31. Rathi S. Physicochemical Characterization and In-Vitro Dissolution Enhancement of Ranolazine Using Solid Dispersion Method. Available at SSRN 3507970. 2019 Dec 21.
32. Raval AM, Bhavsar PR, Pandya FU, Patel D. Co-processed excipients in pharmaceutical formulation: advances, characterization, and applications. Asian Journal of Pharmaceutical Research and Development. 2026 Feb 16;14(01):105-13.

33. Patel N, Raval AM. Gastro-retentive drug delivery system: A review. Int J Pharm Sci. 2026;4(1):734-42.
34. Zankhwala MF, Raval MA, Kushkiwala MA, Sarvaiya MS, Raval MK, Thakar MN, Barjod MS. Formulation And Evaluation Of Optimized Polymer Blends For Diclofenac Diethylamine Transdermal System. The Review of Diabetic Studies. 2025 Sep 14:701-8.
35. Kushkiwala AM, Zankhwala FM, Patel MD, Raval AM. Flurbiprofen loaded ethosomal gel: Design, optimization, and anti-inflammatory activity. Int J Res Anal Rev. 2024;11(4):709-42.
36. Raval MA, Suthar MA, Durani MB, Thakar MN, Zankhwala MF, Kushkiwala MA, Rathod MS. Smart Co-Processed Excipient Platforms: A Novel Strategy for Multifunctional Optimization of Ibuprofen Tablet Formulations. practice.;1:2.
37. Patel PS, Raval AM, Kumar PA, Kumar PP, Ghanshyam PT. A comprehensive review of antibiotic resistance: mechanisms, causes, and novel therapeutic approaches. Asian Journal of Pharmaceutical Research and Development. 2026 Apr 15;14(2):117-28.
38. Raval AM, Rana T, Joshi SY, Buch S, Arora B, Patel VS. Artificial intelligence in pharmacy and healthcare: applications in drug discovery, precision medicine, clinical practice, and future perspectives. Asian Journal of Pharmaceutical Research and Development. 2026 Apr 15;14(2):62-9.
39. Senjaliya T, Patel M, Raval AM. Strategies for combating the global health threat of antibiotic resistance: novel therapeutics and combination approaches. Asian Journal of Pharmaceutical Research and Development. 2026 Feb 15;14(01):122-30.
40. Thakor AD, Dharajiya RM, Shaikh MZ, Raval AM. A review on neuropharmacology: mechanisms, drug classes, and clinical applications. Asian Journal of Pharmaceutical Research and Development. 2026 Feb 15;14(01):114-21.
41. kumar Patel PB, Raval AM, Patel HB, Patel KH, Poorv P, Vaidya PA, Kahar KH. A comprehensive review of polycystic ovary syndrome (PCOS): pathophysiology, diagnosis and management. Asian Journal of Pharmaceutical Research and Development. 2026 Apr 15;14(2):32-41.
42. Raval AM, Maneklal RJ, Dilipbhai MU. Development and Evaluation of PolyherbalTopical Cream for Wound Healing Applications Using Alum, Turmeric, and Aloe Vera. Asian Journal of Pharmaceutical Research and Development. 2026 Apr 15;14(2):234-40.

43. Raval AM, Utpalkumar PF, Utpalkumar PV, Ratnakar BP. Development and Evaluation of Multifunctional Co-Processed Excipients for Fast Dissolving Tablet Formulation. Asian Journal of Pharmaceutical Research and Development. 2026 Apr 15;14(2):226-33.
44. Raval AM, Verma AR, Prajapati DS. Efficacy and Safety of Major Antihypertensive Drug Classes in Adults with Hypertension: A Systematic Review. Asian Journal of Pharmaceutical Research and Development. 2026 Apr 15;14(2):216-25.
45. Raval AM, Chaudhari KN, Arora B, Ukani A, Modh R, Choubisa K, Kumar A. Emerging Role of GLP-1 and Dual Incretin Agonists in the Management of Type 2 Diabetes Mellitus: Mechanisms, Clinical Evidence, Dosing Strategies, and Future Perspectives. International Journal of Medical and Pharmaceutical Research. 2026 May 13; 7:357-70.
46. Panthaki J, Bhai YL, Kumar VS, Raval AM. Formulation and Evaluation of Body Scrub Using Walnut Shell Powder. Asian Journal of Pharmaceutical Research and Development. 2026 Apr 15;14(2):241-7.
47. Upadhyay J, Yadav P, Patel D, Raval A, Patel J. Review on in-situ depot-based controlled drug delivery for treatment of rheumatoid arthritis treatment. World Journal of Pharmaceutical and Medical Research. 2025 Nov;11(11):113-117. doi:10.5281/zenodo.17483326
48. Goswami V, Shukla R, Patel B, Suthar A, Patel P, Raval AM. HPTLC method development and validation for simultaneous estimation of rifaximin and metronidazole benzoate in combined tablet dosage form. Int J Drug Deliv Technol. 2026;16(46s):257-265. doi:10.25258/ijddt.16.46s.27.
49. Kumar PA, Mohmmed N, Chandragirivar PC, Raval AM. Design space exploration of trazodone nanocrystals via DOE: formulation and in vitro-in vivo assessment. Int J Drug Deliv Technol. 2026;16(42s):1358-1368. doi:10.25258/ijddt.16.42s.146.
50. Chandragirivar PC, Banu A, Raval AM, Kusuma R, Srinidhi G, Yashwanth HB, Suheel A. Improved dissolution performance of fenoprofen calcium using PEG 6000 solid dispersions: preparation by fusion method and physicochemical characterization. Int J Drug Deliv Technol. 2026;16(36s):771-781. doi:10.25258/ijddt.16.36s.87.
51. Joshi SY, Detholia KK, Raval AM, Dharu NR, Rathod SR, Kushkiwala AM. Development and validation of a stability-indicating RP-HPLC method for quantitative estimation of sunitinib malate in pharmaceutical dosage form. Int J Drug Deliv Technol. 2026;16(12s):418-426. doi:10.25258/ijddt.16.12s.48.

52. Bhatt R, Raval AM, Patel J, Patel D. Oral thin film drug delivery systems for thrombosis therapy: a comprehensive review. Int J Pharm Sci. 2026;4(1):3563-3576. doi:10.5281/zenodo.18423515.
53. Prajapati A, Yadav P, Raval AM, Patel J. Review on solid dispersion-based fast dissolving tablets: formulation approaches and evaluation. World J Pharm Med Res. 2025;11(11):109-112. doi:10.5281/zenodo.17483241.